TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Senores Pharmaceuticals L
SENORES

Senores Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 66/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,355.2

Change

+10.9 (0.81%)

Open

₹1,344.3

Prev. Close

₹1,344.3

Day High

₹1,394.4

Day Low

₹1,336.3

Volume Analysis

Traded

280,996

Delivered

105,485

Delivery %

37.54%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (29.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (42.9%)
  • •Strong 3-year revenue growth (162.5%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,445.74 ₹1,420.07 ₹1,387.64 ₹1,361.97 ₹1,329.54 ₹1,303.87 ₹1,271.44
Fibonacci ₹1,420.07 ₹1,397.88 ₹1,384.16 ₹1,361.97 ₹1,339.78 ₹1,326.06 ₹1,303.87
Camarilla ₹1,371.18 ₹1,365.85 ₹1,360.53 ₹1,361.97 ₹1,349.87 ₹1,344.55 ₹1,339.22

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+63.98%

1 Week

-2.86%

1 Month

-8.56%

3 Months

+1.9%

6 Months

+75.19%

1 Year

+101.19%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹338.25

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.77%

Net margin 19.04% × asset turnover 0.39x × equity multiplier 1.72x

Company Overview

Sector

Healthcare

Market Cap

₹6,241 Cr

P/E (TTM)

49.4

ROE

13.4%

Book Value

₹203.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Senores Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Growth (100/100), while Valuation (8/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%). Strong 3-year EPS growth (42.9%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

96

Growth

100

Valuation

8

Cash Flow

41

Corporate Governance

56

Momentum

74

Institutional Ownership

42

Business Quality

81

Risk & Volatility

62

Liquidity

67

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 6.69 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 13.9% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Shareholder Meeting / Postal Ballot-Outcome of AGM 25 Sep 25 Sep
Closure of Trading Window 24 Sep 24 Sep
Clarification On Movement In Volume 21 Sep

Company clarified volume movement and said no undisclosed or impending corporate action exists.

Clarification sought from Senores Pharmaceuticals Ltd 21 Sep

Exchange has sought clarification from Senores Pharmaceuticals Ltd on September 21, 2026, with reference to Movement in Volume.

Successful Completion Of USFDA Inspection 11 Sep

USFDA completed inspection at Apnar Pharma’s Vadodara facility on September 11, 2026; one minor procedural observation.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 79 102 80 101 103 114 138 162 171 175 180
Expenses + 64 80 59 77 77 95 104 112 121 128 126
Operating Profit 15 22 21 23 26 19 34 50 50 47 54
OPM % 19.0% 22.0% 27.0% 23.0% 25.0% 17.0% 25.0% 31.0% 29.0% 27.0% 30.0%
Other Income + 1 2 0 2 5 12 3 5 7 18 3
Interest 2 3 5 5 6 5 5 6 5 8 7
Depreciation 3 4 4 4 4 5 6 8 8 9 10
Profit before tax 10 18 13 16 20 21 26 41 45 47 39
Tax % 31.0% 19.0% 19.0% 18.0% 20.0% 13.0% 20.0% 26.0% 25.0% 23.0% 23.0%
Net Profit + 7 14 11 13 16 18 21 30 34 37 30
EPS in Rs 2 5 3 4 4 4 4 7 7 7 7
Raw PDF — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 14 35 215 398 633 688
Expenses + 12 23 173 309 464 487
Operating Profit 2 13 42 90 168 201
OPM % 14.0% 36.0% 19.0% 23.0% 27.0% 29.0%
Other Income + 0 4 3 19 47 33
Interest 1 2 9 22 25 27
Depreciation 1 2 10 17 31 35
Profit before tax 1 12 25 71 159 172
Tax % 13.0% 32.0% -31.0% 17.0% 24.0% —
Net Profit + 1 8 33 58 122 131
EPS in Rs 1 9 10 13 25 27
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 28 36 174 740 888
Borrowings + 15 63 258 315 342
Other Liabilities + 8 23 160 126 328
Total Liabilities 59 131 622 1,227 1,604
Fixed Assets + 7 27 235 301 755
CWIP 8 34 97 172 17
Investments 15 16 0 0 4
Other Assets + 29 53 289 754 827
Total Assets 59 131 622 1,227 1,604
Equity Capital 9 10 31 46 46

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -10 -1 -26 -46 62
Cash from Investing Activity + -24 -48 -54 -429 -121
Cash from Financing Activity + 36 46 87 573 -1
Net Cash Flow 2 -3 8 98 -60
CFO/OP -526 3 -56 -41 45
Free Cash Flow -21 -48 -78 -203 -203

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 45.77% → 45.82%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 38.2% 40.39% 41.03% 41.3% 41.54% 40.92% 37.78%
Promoters 45.77% 45.78% 45.78% 45.8% 45.81% 45.82% 45.82%
FII 4.25% 4.17% 3.66% 4.28% 3.35% 3.64% 6.62%
DII 11.77% 9.66% 9.51% 8.62% 9.32% 9.62% 9.77%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Senores Pharmaceuticals L (this stock) 6,241 49.4 6.67 13.4%
Orchid Pharma Limited 6,377 353.0 3.55 1.49%
Symbiotec Pharmalab Ltd 6,447 64.8 — 11.7%
Iol Chem And Pharma Ltd 5,965 33.8 3.31 8.41%
Artemis Med Service Ltd 5,917 51.0 6.34 12.0%
Morepen Lab. Ltd 6,596 56.2 5.26 5.33%
Kovai Medical Center & Ho 6,653 115.0 23.07 22.2%

Which Mutual Funds Hold Senores Pharmaceuticals L?

Frequently Asked Questions about Senores Pharmaceuticals L

Community Sentiment

What are other investors saying about Senores Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.